• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Vor Biopharma Inc (NQ: VOR )

    0.8600 +0.0800 (+10.26%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Vor Biopharma Inc

    < Previous 1 2 Next >
    Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer
    From Vor Biopharma
    Via GlobeNewswire
    New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio to Participate in Upcoming Investor Conferences
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio to Participate in Upcoming Investor Conferences
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio to Participate in Upcoming Investor Conferences
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio to Participate in Upcoming Investor Conferences
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio to Participate in Upcoming Investor Conferences
    From Vor Biopharma
    Via GlobeNewswire
    Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio’s Novel eHSC and CAR-T Platform
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio to Participate in Upcoming Investor Conferences
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio to Participate in Upcoming Investor Conferences
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio Reports Second Quarter 2023 Financial Results and Provides Company Update
    From Vor Biopharma
    Via GlobeNewswire
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.